Literature DB >> 15006704

Cu/Zn-superoxide dismutase (GLY93-->ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture.

Alida Spalloni1, Federica Albo, Francesca Ferrari, Nicola Mercuri, Giorgio Bernardi, Cristina Zona, Patrizia Longone.   

Abstract

The cause of the selective degeneration of motor neurons in amyotrophic lateral sclerosis (ALS) remains a mystery. One potential pathogenic mechanism is excitotoxicity due to disturbances of glutamatergic neurotransmission, particularly via AMPA-sensitive glutamate receptors. We report here that motor neurons from a familial ALS-linked superoxide dismutase (SOD1) mutant G93A mouse show an higher susceptibility to kainate-induced excitotoxicity. Moreover, they expressed GluR(3) and GluR(4) mRNA at detectable levels more frequently, with a modified electrophysiology when compared with control and wild-type SOD1 motor neurons. Thus, the SOD1 G93A mutation causes changes in the AMPA-receptor expression and function, as well as a susceptibility to kainate-mediated excitotoxicity, which may promote the motor neuron degeneration seen in ALS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006704     DOI: 10.1016/j.nbd.2003.11.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  14 in total

Review 1.  Molecular and cellular pathways of neurodegeneration in motor neurone disease.

Authors:  P J Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

2.  Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons.

Authors:  Christian S Lobsiger; Séverine Boillée; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

3.  Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration.

Authors:  J Simon Lunn; Stacey A Sakowski; Bhumsoo Kim; Andrew A Rosenberg; Eva L Feldman
Journal:  Dev Neurobiol       Date:  2009-11       Impact factor: 3.964

Review 4.  Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?

Authors:  H Muyderman; T Chen
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

5.  Lithium delays progression of amyotrophic lateral sclerosis.

Authors:  Francesco Fornai; Patrizia Longone; Luisa Cafaro; Olga Kastsiuchenka; Michela Ferrucci; Maria Laura Manca; Gloria Lazzeri; Alida Spalloni; Natascia Bellio; Paola Lenzi; Nicola Modugno; Gabriele Siciliano; Ciro Isidoro; Luigi Murri; Stefano Ruggieri; Antonio Paparelli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

Review 6.  In vivo brain imaging of mitochondrial Ca2+ in neurodegenerative diseases with multiphoton microscopy.

Authors:  Maria Calvo-Rodriguez; Elizabeth K Kharitonova; Brian J Bacskai
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-03-05       Impact factor: 4.739

7.  Riluzole But Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral Sclerosis.

Authors:  Manoj Kumar Jaiswal
Journal:  Front Cell Neurosci       Date:  2017-01-06       Impact factor: 5.505

Review 8.  The wobbler mouse, an ALS animal model.

Authors:  Jakob Maximilian Moser; Paolo Bigini; Thomas Schmitt-John
Journal:  Mol Genet Genomics       Date:  2013-03-29       Impact factor: 3.291

Review 9.  Mitochondrial Ca(2+) and neurodegeneration.

Authors:  Tito Calì; Denis Ottolini; Marisa Brini
Journal:  Cell Calcium       Date:  2012-05-18       Impact factor: 6.817

10.  A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis.

Authors:  Nico Melzer; Sven G Meuth; Delany Torres-Salazar; Stefan Bittner; Alla L Zozulya; Christian Weidenfeller; Alexandra Kotsiari; Martin Stangel; Christoph Fahlke; Heinz Wiendl
Journal:  PLoS One       Date:  2008-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.